SCHEMBL7444597

SCHEMBL7444597

CCC(C)Oc1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 1/20 0.47
GABRD O14764 1/20 0.47
GABRA1 P14867 1/20 0.47
GABRB1 P18505 1/20 0.47
GABRG2 P18507 1/20 0.47
GABRB3 P28472 1/20 0.47
GABRA5 P31644 1/20 0.47
GABRA3 P34903 1/20 0.47
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
GABRA4 P48169 1/20 0.47
GABRE P78334 1/20 0.47
GABRA6 Q16445 1/20 0.47
GABRG1 Q8N1C3 1/20 0.47
GABRG3 Q99928 1/20 0.47
GABRQ Q9UN88 1/20 0.47
DYRK1A Q13627 2/20 0.41
DYRK2 Q92630 2/20 0.41
KCNA5 P22460 2/20 0.40
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12549545 1.00 GABRP (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9266415 0.86 GABRP (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12124947 0.85 KCNA5 (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2913253 0.83 DYRK1A (0.40) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2356476 0.83 DYRK1A (0.43) DYRK1ADYRK2KCNA5NPC1RAB9A
SCHEMBL7678732 0.83 DYRK1A (0.40) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2356474 0.83 DYRK1A (0.40) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15140316 0.83 DYRK1A (0.43) DYRK1ADYRK2KCNA5KCNH2NPC1
SCHEMBL8783394 0.83 DYRK1A (0.43) DYRK1ADYRK2KCNA5NPC1RAB9A
SCHEMBL9270377 0.82 GPBAR1 (0.38) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4318630-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY ASAHI CHEMICAL IND (JP) 2025-10-22 EP disclosed
CN-119954801-A TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-05-09 CN disclosed
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-01-14 US disclosed
EP-4415105-A2 NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE Asahi Kasei Kabushiki Kaisha (JP) 2024-08-14 EP disclosed
US-20240178452-A1 Nonaqueous Electrolyte Solution and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-05-30 US disclosed
EP-4318630-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2024-02-07 EP disclosed
CN-117223143-A Nonaqueous electrolyte and nonaqueous secondary battery 旭化成株式会社 2023-12-12 CN disclosed
WO-2022203072-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY 旭化成株式会社 2022-09-29 WO disclosed
US-20220293929-A1 Non-Aqueous Secondary Battery and Non-Aqueous Electrolyte ASAHI KASEI KABUSHIKI KAISHA (JP) 2022-09-15 US disclosed
EP-4009398-A1 NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE Asahi Kasei Kabushiki Kaisha (JP) 2022-06-08 EP disclosed
CN-114342145-A Nonaqueous secondary battery and nonaqueous electrolyte 旭化成株式会社 2022-04-12 CN disclosed
US-10693189-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-06-23 US disclosed
CN-107431247-B Nonaqueous electrolyte solution and nonaqueous secondary battery 旭化成株式会社 2020-02-21 CN disclosed
EP-3279996-B1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI CHEMICAL IND (JP) 2018-12-26 EP disclosed
US-20180062207-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
EP-3279996-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2018-02-07 EP disclosed
EP-0977743-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-02-09 EP disclosed
WO-1998049152-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220293929-A1 Non-Aqueous Secondary Battery and Non-Aqueous Electrolyte CLK2, TYK2, CLK3 GABRP 4768/4885GABRD 4810/4885GABRA1 4738/4885
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte CLK2, TYK2, CLK3 GABRP 4768/4885GABRD 4810/4885GABRA1 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.